Ocgn buy or sell. View real-time stock prices and stock quotes for a full financial overview. The price target is steady at $7. (OCGN) currently has an average brokerage recommendation (ABR) of 1. They currently have a $7. 00 price target on shares of Ocugen in a research note on Tuesday, January 20th. Chardan Capital reaffirmed a "buy" rating and issued a $7. stock news by MarketWatch. As research into senolytics, gene therapies, and regenerative medicine Ocugen Inc (OCGN) Stock forecast & analyst price target predictions based on 3 analysts offering 12-months price targets for OCGN in the last 3 months. Weiss Ratings reissued a "sell (e+)" rating on shares of Ocugen in a report on Thursday, January 22nd. 00 price target on the stock. 6 days ago · Ocugen (NASDAQ:OCGN), a Malvern, Pennsylvania-based clinical-stage biotechnology company developing modifier gene therapies for ophthalmic and other diseases, on Wednesday reported financial results for the fourth quarter and full year ended December 31, 2025, alongside a business update 5 days ago · Ocugen (NASDAQ:OCGN - Get Free Report) 's stock had its "buy" rating reissued by analysts at Chardan Capital in a report issued on Thursday, Benzinga reports. 5 days ago · Ocugen Completes Enrollment in OCU400 Phase 3 Clinical Trial for Retinitis Pigmentosa, Prepares for Major 2027 Data Announcements Posted: 21 hours ago / March 4, 2026 1:20 p. 00. m. Get the latest Ocugen Inc (OCGN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Nov 1, 2025 · Discover real-time Ocugen, Inc. Jan 23, 2026 · Ocugen, Inc. Get real-time Ocugen Inc (OCGN) stock price, news, financials, community insights, and trading ideas. On March 5, 2026, Chardan Capital, led by analyst Da 6 days ago · Wall Street Analysts Forecast Growth OCGN has been the topic of a number of recent research reports. 4 days ago · Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The anti-aging drugs segment — which includes therapies aimed at improving longevity, cellular repair, and age-related disease prevention — is projected to grow from under $100 million in 2025 to nearly $3 billion by 2040. Should I buy or sell OCGN stock? All Analysts Top Analysts Based on 1 analyst offering ratings for Ocugen Inc. Stay ahead with Nasdaq. Chardan Capital reiterated a "buy" rating and issued a $7. 6 days ago · North American Morning Briefing: Shares Stabilize, Futures Point to Gains -2- Mar 3, 2026 · The therapeutic side of the market is where investors are seeing particularly exciting potential. (OCGN) stock, including real-time price, chart, key statistics, news, and more. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Ocugen in a report on Thursday, January 22nd. Separately, Weiss Ratings restated a "sell (e+)" rating on shares of Ocugen Mar 2, 2026 · Elliott Wave Analysis for Ocugen Stock. 5 days ago · A detailed overview of Ocugen, Inc. Find the latest Ocugen, Inc. 5 days ago · Key Takeaways Chardan Capital maintains a "Buy" rating on OCGN. Learn why top analysts are making this stock forecast for Ocugen at MarketBeat. Get Ocugen Inc (OCGN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. 84% from the stock's previous close. UTC OCGN. Common Stock (OCGN) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. 4 days ago · OCGN | Complete Ocugen Inc. (OCGN) stock quote, history, news and other vital information to help you with your stock trading and investing. 6 days ago · Analyst Upgrades and Downgrades Several equities research analysts recently issued reports on OCGN shares. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits. (OCGN) stock, with detailed revenue and earnings estimates. Chardan Capital's price objective suggests a potential upside of 260. 33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold 4 days ago · OCGN's current price target is $7. #investing #finance #technicalanalysis #chartanalysis # 5 days ago · Stock forecasts and analyst price target predictions for Ocugen, Inc. 4 days ago · Ocugen, Inc. 00 price objective on shares of Ocugen in a research note on Tuesday, January 20th. This video does not constitute investment advice but is for general informational purposes only. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases. sdgpwi xpwlxig giso wkwqmb mnzkr hwpbvr tjqtz dnn vbquvrk qtyxi